WallStSmart

Berkshire Hathaway Inc (BRK-A)vsDrugs Made In America Acquisition II Corp. Ordinary Shares (DMII)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

BRK-A leads profitability with a 22.3% profit margin vs 0.0%. BRK-A trades at a lower P/E of 12.8x. BRK-A earns a higher WallStSmart Score of 74/100 (B).

BRK-A

Strong Buy

74

out of 100

Grade: B

Growth: 7.3Profit: 7.5Value: 5.0Quality: 8.5
Piotroski: 4/9Altman Z: 2.59

DMII

Avoid

32

out of 100

Grade: F

Growth: 4.3Profit: 3.5Value: 4.7Quality: 5.3
Piotroski: 3/9

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BRK-A6 strengths · Avg: 9.7/10
Market CapQuality
$1.09T10/10

Mega-cap, among the largest globally

Price/BookValuation
1.5x10/10

Reasonable price relative to book value

Operating MarginProfitability
32.6%10/10

Strong operational efficiency at 32.6%

EPS GrowthGrowth
107.8%10/10

Earnings expanding 107.8% YoY

Profit MarginProfitability
22.3%9/10

Keeps 22 of every $100 in revenue as profit

Debt/EquityHealth
0.179/10

Conservative balance sheet, low leverage

DMII1 strengths · Avg: 10.0/10
Debt/EquityHealth
0.0010/10

Conservative balance sheet, low leverage

Areas to Watch

BRK-A1 concerns · Avg: 2.0/10
PEG RatioValuation
9.682/10

Expensive relative to growth rate

DMII4 concerns · Avg: 3.8/10
P/E RatioValuation
35.0x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$647.37M3/10

Smaller company, higher risk/reward

Comparative Analysis Report

WallStSmart Research

Bull Case : BRK-A

The strongest argument for BRK-A centers on Market Cap, Price/Book, Operating Margin. Profitability is solid with margins at 22.3% and operating margin at 32.6%.

Bull Case : DMII

The strongest argument for DMII centers on Debt/Equity.

Bear Case : BRK-A

The primary concerns for BRK-A are PEG Ratio.

Bear Case : DMII

The primary concerns for DMII are P/E Ratio, Revenue Growth, EPS Growth.

Key Dynamics to Monitor

BRK-A profiles as a mature stock while DMII is a value play — different risk/reward profiles.

BRK-A is growing revenue faster at 10.0% — sustainability is the question.

BRK-A generates stronger free cash flow (5.6B), providing more financial flexibility.

Monitor INSURANCE - DIVERSIFIED industry trends, competitive dynamics, and regulatory changes.

Bottom Line

BRK-A scores higher overall (74/100 vs 32/100), backed by strong 22.3% margins. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Berkshire Hathaway Inc

FINANCIAL SERVICES · INSURANCE - DIVERSIFIED · USA

Berkshire Hathaway Inc. is an American multinational conglomerate holding company headquartered in Omaha, Nebraska, United States. The company wholly owns GEICO, Duracell, Dairy Queen, BNSF, Lubrizol, Fruit of the Loom, Helzberg Diamonds, Long & Foster, FlightSafety International, Pampered Chef, Forest River, and NetJets, and also owns 38.6% of Pilot Flying J; and significant minority holdings in public companies Kraft Heinz Company (26.7%), American Express (18.8%), The Coca-Cola Company (9.32%), Bank of America (11.9%), and Apple (6.3%).

Visit Website →

Drugs Made In America Acquisition II Corp. Ordinary Shares

FINANCIAL SERVICES · SHELL COMPANIES · USA

Drugs Made In America Acquisition II Corp. (DMII) is a special purpose acquisition company (SPAC) focused on identifying and merging with innovative players in the pharmaceuticals and biotechnology sectors, prioritizing advancements in domestic drug manufacturing. Leveraging a seasoned management team with considerable industry expertise, DMII aims to execute strategic transactions that respond to market dynamics and foster sustainable practices. The company's mission encompasses enhancing supply chain resilience and promoting U.S. healthcare self-sufficiency, ultimately driving long-term value creation for shareholders and contributing to the growth of the American pharmaceutical landscape.

Want to dig deeper into these stocks?